Sionna Therapeutics, INC

Sionna Therapeutics reported Q1 2026 financial results, highlighting progress in its cystic fibrosis drug development programs with key trial data anticipated in summer 2026 and a strong cash position extending into 2028.

Sionna Therapeutics announced its full-year 2025 financial results and provided updates on its cystic fibrosis pipeline, including anticipated mid-2026 topline data.

Sionna Therapeutics initiated two new clinical trials for its cystic fibrosis drug candidates and reported a strong cash position expected to fund operations into 2028.

Sionna Therapeutics announced positive Phase 1 data for SION-719 and SION-451, maintaining a strong cash position expected to fund operations into 2028, and progressing its cystic fibrosis pipeline.

Sionna Therapeutics, Inc. announced the successful election of three Class I directors and the ratification of Deloitte & Touche LLP as its independent registered public accounting firm at its Annual Meeting of Stockholders held on June 12, 2025.

Sionna Therapeutics reported positive Phase 1 clinical trial results for its NBD1 stabilizers, SION-719 and SION-451, for cystic fibrosis, leading to the advancement of both programs into further clinical development.

Sionna Therapeutics reported a net loss of $26.8 million for Q1 2026, with increased operating expenses primarily in R&D and G&A, while maintaining a cash runway projected into 2028.

Sionna Therapeutics reported a net loss of $20.3 million for Q3 2025, advancing its lead cystic fibrosis drug candidates SION-719 and SION-451 into later-stage clinical trials.

Sionna Therapeutics announced positive topline Phase 1 data for its lead NBD1 stabilizer candidates, SION-719 and SION-451, while reporting increased operating losses for Q2 2025.

Sionna Therapeutics reports a net loss of $16.5 million for Q1 2025, highlighting ongoing investments in research and development for its cystic fibrosis therapies.

Sionna Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $75.3 million for 2025 while advancing its lead cystic fibrosis product candidates, SION-719 and SION-451, into later-stage clinical trials.

Sionna Therapeutics' 10-K filing details its ongoing clinical trials and development of novel medicines for cystic fibrosis (CF), focusing on NBD1 stabilizers and complementary modulators.

Sionna Therapeutics Director Peter A. Thompson reported a sale of 85,918 shares of common stock on July 7, 2026, executed under a Rule 10b5-1 trading plan.

OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC have reported the sale of 85,918 shares of Sionna Therapeutics, Inc. common stock.

Jennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics, Inc., sold 10,250 shares of common stock for approximately $43.60 per share under a pre-arranged 10b5-1 trading plan.

Sionna Therapeutics Director Peter A. Thompson reported a sale of 115,844 shares of common stock on June 30, 2026, executed under a Rule 10b5-1 trading plan.

OrbiMed Advisors LLC, a significant holder, has reported the sale of 115,844 shares of Sionna Therapeutics, Inc. common stock on June 30, 2026, executed under a Rule 10b5-1(c) trading plan.

Laurie Stelzer, a Director at Sionna Therapeutics, Inc., was granted 17,340 non-qualified stock options with an exercise price of $36.73.

Sionna Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 17, 2026, with key proposals including director elections and auditor ratification.

Sionna Therapeutics announces its 2025 Annual Meeting of Stockholders, featuring director elections and ratification of the independent accounting firm.

Sionna Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, featuring proposals for director elections and auditor ratification.

Sionna Therapeutics files a Form S-1 to register an additional 2,029,409 shares of common stock, including those for underwriters' over-allotment option, after its initial S-1 was declared effective.

Sionna Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its novel medicines targeting the NBD1 domain of the CFTR protein for cystic fibrosis treatment.

Sionna Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering to fund the development of novel medicines for cystic fibrosis.

OrbiMed Advisors and OrbiMed Capital GP VIII have reduced their beneficial ownership in Sionna Therapeutics, Inc. by selling shares via a 10b5-1 plan.

RA Capital Management and its affiliates report a dilution of their beneficial ownership in Sionna Therapeutics, Inc. to 22.6% of common stock outstanding.

Atlas Venture entities have reduced their collective beneficial ownership in Sionna Therapeutics, Inc. to 7.0% through recent share sales.

TPG GP A, LLC and its principals, James G. Coulter and Jon Winkelried, have disclosed a significant 15.2% beneficial ownership in Sionna Therapeutics, Inc. following the company's recent Initial Public Offering.

Atlas Venture entities have filed a Schedule 13D, revealing a collective 8.4% beneficial ownership in Sionna Therapeutics, primarily acquired prior to and during the company's recent initial public offering.

RA Capital Management and its affiliates have filed a Schedule 13D, revealing a significant 23.7% beneficial ownership in Sionna Therapeutics, Inc. common stock following the company's recent Initial Public Offering.

Viking Global Investors filed an amended Schedule 13G to reflect the retirement of David C. Ott from its reporting group.

Qatar Investment Authority and its subsidiary Q Healthcare Holding LLC have reported beneficial ownership of 4.5% of Sionna Therapeutics Inc. common stock as of March 31, 2026.

JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, disclosing a 4.4% beneficial ownership stake in Sionna Therapeutics, Inc.

JPMorgan Chase & Co. has reported a 5.0% beneficial ownership stake in Sionna Therapeutics, Inc., holding 2,221,188 shares of common stock.

Qatar Investment Authority and its affiliate, Q Healthcare Holding LLC, have disclosed a 5.0% beneficial ownership stake in Sionna Therapeutics Inc, holding 2,209,775 shares of Common Stock.

Viking Global Investors LP and its affiliates have reported a beneficial ownership of 6.7% in Sionna Therapeutics, Inc. common stock, totaling 2,952,754 shares, following the company's recent initial public offering.